Gene

ABL2

ABL proto-oncogene 2, non-receptor tyrosine kinase

Explore in graph →CI-GENE-00000154HGNC:77 ENSG00000143322 NCBI 27 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (29)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–29 of 29 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL2 W469C1
Dasatinib + ImatinibSubstitutes	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	accepted

Cohorts

Alteration frequency by cohort (14)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved14 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015) cscc_dfarber_2015	Skin Squamous Cell Carcinoma	Ssm	5

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.
· EMBO Mol Med · 2016 · PMID 26758680 · validated civic_curation pubmed

ABL2 Y399C1
Dasatinib + ImatinibSubstitutes	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	rejected	EID10078 Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic

ABL2 Y399C1

Dasatinib + ImatinibSubstitutes

Lung Adenocarcinoma

Predictive

Does Not Support Sensitivity Response

rejected

EID10078

Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

ABL2 Fusion2
(oncogenic)	Acute Myeloid LeukemiaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	1	submitted	EID12491 The HT93A cell line was established from a patient with acute myelogenous leukemia (AML-M3). The patient was a 66 yr old man and was successfully induced to first and second remission with combined ch… (full text at CIViC) PMID 10706884 · Iijima et al., 2000 · Open in CIViC	civic
〃	B Acute Lymphoblastic LeukemiaALIAS	Oncogenic	C	Supports Oncogenicity	1	submitted	EID12493 In a study of 176 ALL patients, consisting of 136 B- and 40 T-lineage, multiplex nested RT-PCR was used to look for ETV6 fusions. One patient had ETV6::ABL2 fusion. Patient was a 17 year old with kary… (full text at CIViC) PMID 22373549 · Zhou et al., 2012 · Open in CIViC	civic

ABL2 Fusion4
(oncogenic)	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Oncogenic	C	Supports Oncogenicity	2	submitted	EID9721 In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12872 In a study using whole genome, exome and transcriptome sequencing of 2,754 childhood ALL patients, one patient with Ph-like B-ALL had PAG1::ABL2 reported. Patient ID was SJBALL020980. RNAseq, WES, WGS… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC	civic
〃	Acute Lymphoblastic Leukemia	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12873 Ba/F3 cells transduced with PAG1::ABL2 Fusion were found to show IL3 independent growth. Phosphoflow cytometric analysis showed increased phospho-STAT5, phospho-CRKL, and phospho-S6 over control Ba/F3… (full text at CIViC) PMID 29296813 · Roberts et al., 2017 · Open in CIViC	civic
Dasatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID12874 Ba/F3 cells transduced with PAG1::ABL2 Fusion were IL3 growth independent, and treated with dasatinib for 48 hours at different concentrations up to 50 nM. IC50 for viable cells (as percentage of untr… (full text at CIViC) PMID 29296813 · Roberts et al., 2017 · Open in CIViC	civic

ABL2 Fusion8
(oncogenic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	N/A N/A	3	rejected	EID9722 Type evidence here PMID 27125982 · Perwein et al., 2016 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	3	submitted	EID9768 In a cohort Dutch/German patients (age <15 years) with B cell precursor acute lymphoblastic leukemia, 14 tyrosine kinase fusions were identified among 77 BCR-ABL1-like cases, and zero were identified … (full text at CIViC) PMID 27894077 · Boer et al., 2017 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	3	submitted	EID9769 In a study of Transcriptome sequencing to identify fusions and mutations on 560 ALL Patients enrolled on a multi-center Alliance, two patients were identified to carry the RCSD1-ABL2 fusion. One was a… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC	civic
(diagnostic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Diagnostic	C	Supports Positive	3	submitted	EID9770 A 20-year-old male patient was diagnosed with precursor B-ALL (immunophenotype: CD34+, DR+, TdT+, CD19+, CD20 partial+, CD10+, cyCD79a+, CD24+, surface/cyCD22+, cyIgM+, sIg−, MPO−, CD13+, CD33+). Chro… (full text at CIViC) PMID 25098428 · Raca et al., 2015 · Open in CIViC	civic
(oncogenic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	submitted	EID9771 In a study of 1389 consecutively enrolled, newly diagnosed patients with B-ALL, two male patients with high risk Ph-like disease were identified to carry RCSD1-ABL2 fusion by RT-PCR and are eligible t… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9773 To investigate the functional role and targetability of the tyrosine kinase fusions identified in Ph-like ALL, murine Arf−/− pre-B ALL expressing tyrosine kinase fusions were developed. It showed that… (full text at CIViC) PMID 29296813 · Roberts et al., 2017 · Open in CIViC	civic
Dasatinib	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	D	Supports Sensitivity Response	3	accepted	EID7251 The RCSD1-ABL2 fusion was identified in a 5 yo boy with Ph-like B-ALL and Klinefelter syndrome. Following standard induction therapy the patient had an MRD of 1.2% in bone marrow, and continued to be … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic
Imatinib	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	3	submitted	EID9772 A 5 year-old male patient with B-ALL was described with an initial WBC of 57,700 (Supplementary Appendix 2). Chromosome analysis showed 47,XXYc with a confirmed diagnosis of Klinefelter syndrome. FISH… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic